Actuate Therapeutics (NASDAQ:ACTU - Get Free Report)'s stock price traded down 5.4% during mid-day trading on Wednesday . The stock traded as low as $8.44 and last traded at $8.79. 13,214 shares changed hands during mid-day trading, a decline of 68% from the average session volume of 41,467 shares. The stock had previously closed at $9.29.
Actuate Therapeutics Stock Up 0.5 %
The stock has a fifty day moving average price of $8.46.
Institutional Investors Weigh In On Actuate Therapeutics
A hedge fund recently bought a new stake in Actuate Therapeutics stock. Northwestern University purchased a new stake in Actuate Therapeutics (NASDAQ:ACTU - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 27,778 shares of the company's stock, valued at approximately $207,000. Actuate Therapeutics accounts for approximately 0.2% of Northwestern University's investment portfolio, making the stock its 5th biggest position. Northwestern University owned about 0.14% of Actuate Therapeutics at the end of the most recent reporting period.
About Actuate Therapeutics
(
Get Free Report)
Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
Recommended Stories
Before you consider Actuate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Actuate Therapeutics wasn't on the list.
While Actuate Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
